Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials

PURPOSE: Women have more adverse events (AEs) from chemotherapy than men, but few studies have investigated sex differences in immune or targeted therapies. We examined AEs by sex across different treatment domains. METHODS: We analyzed treatment-related AEs by sex in SWOG phase II and III clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Unger, Joseph M., Vaidya, Riha, Albain, Kathy S., LeBlanc, Michael, Minasian, Lori M., Gotay, Carolyn C., Henry, N. Lynn, Fisch, Michael J., Lee, Shing M., Blanke, Charles D., Hershman, Dawn L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061143/
https://www.ncbi.nlm.nih.gov/pubmed/35119908
http://dx.doi.org/10.1200/JCO.21.02377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061143/
https://www.ncbi.nlm.nih.gov/pubmed/35119908
http://dx.doi.org/10.1200/JCO.21.02377

Ejemplares similares